Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent

Showing results (761-770 of 1,192) with videos related to

Pageof 120
Sort By:
The British Journal of Dermatology|August 20, 2022
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group studyMegan N Landis, Mark Arya, Stacy Smith, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Periplasmic detoxification of urate hydroperoxide underpins <i>E. coli</i> survival in the inflamed gutMaxence S Vincent, Laurent Loiseau, Matthew Jones, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 29, 2011
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasoneJesús F San-Miguel, Meletios A Dimopoulos, Edward A Stadtmauer, et al.
British Journal of Haematology|August 21, 2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaSagar Lonial, Paul G Richardson, Jesús San Miguel, et al.
Blood|June 16, 2011
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myelomaSumit Madan, Martha Q Lacy, Angela Dispenzieri, et al.
Blood|October 24, 2002
Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosisAnimesh Pardanani, Thomas E Witzig, Georgene Schroeder, et al.
Clinical and Translational Science|December 8, 2020
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation StudyRavi Shankar P Singh, Vivek Pradhan, Erika S Roberts, et al.
Haematologica|December 7, 2005
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trialDavid Dingli, S Vincent Rajkumar, Grzegorz S Nowakowski, et al.
Journal of the American Academy of Dermatology|March 24, 2021
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week resultsBrett King, Emma Guttman-Yassky, Elena Peeva, et al.
Blood|January 31, 2009
Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significanceCeline M Vachon, Robert A Kyle, Terry M Therneau, et al.
Pageof 120

Showing results (761-770 of 1,192) with videos related to

Sort By:
Pageof 120
The British Journal of Dermatology|August 20, 2022
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group studyMegan N Landis, Mark Arya, Stacy Smith, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Periplasmic detoxification of urate hydroperoxide underpins <i>E. coli</i> survival in the inflamed gutMaxence S Vincent, Laurent Loiseau, Matthew Jones, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 29, 2011
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasoneJesús F San-Miguel, Meletios A Dimopoulos, Edward A Stadtmauer, et al.
British Journal of Haematology|August 21, 2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaSagar Lonial, Paul G Richardson, Jesús San Miguel, et al.
Blood|June 16, 2011
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myelomaSumit Madan, Martha Q Lacy, Angela Dispenzieri, et al.
Blood|October 24, 2002
Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosisAnimesh Pardanani, Thomas E Witzig, Georgene Schroeder, et al.
Clinical and Translational Science|December 8, 2020
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation StudyRavi Shankar P Singh, Vivek Pradhan, Erika S Roberts, et al.
Haematologica|December 7, 2005
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trialDavid Dingli, S Vincent Rajkumar, Grzegorz S Nowakowski, et al.
Journal of the American Academy of Dermatology|March 24, 2021
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week resultsBrett King, Emma Guttman-Yassky, Elena Peeva, et al.
Blood|January 31, 2009
Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significanceCeline M Vachon, Robert A Kyle, Terry M Therneau, et al.
Pageof 120